CellCarta offers an integrated workflow that brings pathology, IHC, tissue genomics, liquid biopsy, and HLA typing inside one sample-aware operating model.
Published
Signal category
Products & Services
Quote
“CellCarta's integrated workflow brings pathology, IHC, tissue genomics, liquid biopsy and HLA typing inside one sample-aware operating model.”
— Jurgen Del Favero|CellCarta team
Company
CellCarta
The Power of More: Generating reliable, regulatory-ready data to support clinical development.
- Industry
- Biotechnology Research
- Location
- Montreal, CA
- Company size
- 760 employees
CellCarta is a leading global CRO laboratory to the biopharmaceutical and biotechnology industries. We partner with translational medicine, biomarker, and clinical development teams to generate reliable, regulatory-ready data that supports complex clinical development. With fully owned and harmonized laboratory operations across North America, Europe, Australia, and China, CellCarta delivers integrated capabilities spanning immunology, histopathology, proteomics, and genomics, supported by comprehensive sample management and logistics solutions. Our scientific teams bring deep expertise and rigorous oversight to every program, guiding assay design, development, validation, and troubleshooting. CellCarta is adept at supporting highly customized, scientifically complex biomarker strategies as well as large-scale, standardized global studies requiring consistent execution across regions. By combining multi-modal insights, specialized scientific insight, and globally harmonized operations, we supports the full biomarker continuum from early translational research through late-stage clinical development and companion diagnostic (CDx) advancement. For more information, visit cellcarta.com